Scienmag
SEPTEMBER 28, 2020
Credit: Edel Pérez-López First described in the 13th century in Russia, clubroot has been affecting worldwide brassica production, including canola, broccoli, and black mustard, since.
Drug Discovery World
NOVEMBER 15, 2022
The brainchild of multidisciplinary experts in computer science, physics, engineering, and biology, the field of synthetic biology has not only rapidly progressed in the last few decades but it’s also becoming more accessible and cost-effective. Synthetic libraries for antibody drug discovery .
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Scienmag
OCTOBER 7, 2020
Computational algorithms enable identification and optimization of RNA-based tools for myriad applications DNA and RNA have been compared to “instruction manuals” containing the information needed for living “machines” to operate.
The Pharma Data
SEPTEMBER 11, 2021
This precise and rational approach to library fabrication combined with sophisticated bioinformatics and software expertise expedites antibody discovery by decreasing risk, increasing speed, and lowering the failure rate for antibody therapeutic development. This press release contains forward-looking statements.
Drug Discovery World
NOVEMBER 30, 2023
Sphere Fluidics presence on the exhibition floor was bolstered by a presentation from Richard Hammond: ‘Picodroplets for cell Line engineering: A novel automation approach’. It was presented by Xiaole Shirley Liu, PhD, CEO, GV20 Therapeutics, and titled: ‘AI-based target and antibody discovery from patient tumour profiles’.
XTalks
DECEMBER 13, 2023
This impressive growth can be attributed to Fulgent’s distinctive chemistries and advanced proprietary bioinformatics pipeline, which have been instrumental in fueling the company’s rapid advancement in recent years. Alpine Immune Sciences has recently announced an augmentation in its R&D investment. million and $38.8 million and $33.9
The Pharma Data
JULY 27, 2021
“Over the last five years, Teneobio developed leading-edge expertise in efficiently engineering differentiated multispecific and bispecific therapeutics for numerous indications with potentially better safety, efficacy and pharmacokinetic profiles than the first generation of T-cell engagers. chief executive officer of Teneobio.
Expert insights. Personalized for you.
52 
Let's personalize your content